Viking Therapeutics (NASDAQ:VKTX) has been given a $8.00 price objective by equities researchers at Maxim Group in a note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target points to a potential upside of 101.51% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Viking Therapeutics in a research report on Friday, November 10th. Roth Capital initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, November 21st. They set a “buy” rating and a $5.00 target price on the stock. Finally, ValuEngine raised shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 7th.

Shares of Viking Therapeutics (NASDAQ VKTX) traded down $0.11 on Tuesday, reaching $3.97. 1,564,200 shares of the company were exchanged, compared to its average volume of 404,881. Viking Therapeutics has a one year low of $0.88 and a one year high of $4.28.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in shares of Viking Therapeutics in the 3rd quarter worth approximately $108,000. Virtu KCG Holdings LLC purchased a new position in shares of Viking Therapeutics in the 2nd quarter worth approximately $124,000. Renaissance Technologies LLC grew its position in shares of Viking Therapeutics by 62.9% in the 1st quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after buying an additional 102,600 shares during the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Viking Therapeutics in the 3rd quarter worth approximately $554,000. Finally, Sabby Management LLC purchased a new position in shares of Viking Therapeutics in the 2nd quarter worth approximately $525,000. 7.40% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Analysts Give Viking Therapeutics (VKTX) a $8.00 Price Target” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/12/maxim-group-analysts-give-viking-therapeutics-vktx-a-8-00-price-target.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.